CLDI · Calidi Biotherapeutics Inc
United States · RS rating 58 · As of 2026-10-14
| Price | 0.87 USD |
|---|---|
| 1-day change | -2.9% |
| RS rating (overall / 1M / 3M / 12M) | 58 / 8 / 99 / 15 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 27 / 26 / 43 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +57.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +53.8% |
| Market cap (USD) | $2.4M |